Finance for Non-Financial Leaders in the Pharmaceutical Industry Training Course

Course overview

In today’s highly regulated and cost-sensitive pharmaceutical environment, financial literacy is no longer optional for business leaders - it’s a strategic necessity. Every decision, from R&D investment to market access and compliance, directly impacts the Profit & Loss (P&L) and long-term value creation.

This intensive two-day interactive workshop is designed specifically for non-financial leaders across the UK and global pharmaceutical sector who need to understand how financial principles integrate with the unique regulatory, pricing and compliance frameworks shaping pharma performance.

Through a mix of hands-on case studies, financial modelling exercises and a capstone simulation, participants will gain practical insight into how financial decisions interact with VPAG pricing, HTA outcomes, IFRS reporting, and compliance obligations under GxP, ABPI, and global anti-bribery frameworks.

By the end of the course, you’ll be able to confidently interpret and explain a pharma P&L, connect operational and regulatory realities to financial outcomes, and apply accounting and compliance standards to real-world business scenarios. You’ll also learn how to anticipate the financial impact of complex issues such as serialisation, managed entry agreements, transfer pricing and global tax reforms.

Whether you lead commercial, operational, or compliance teams, this programme will equip you with the financial fluency and strategic insight to contribute effectively to cross-functional decision-making and drive sustainable growth in a challenging global market.

During this highly interactive course, the expert trainer uses a practical, case-based learning approach that bridges technical finance with pharmaceutical operations, including:

• Interactive simulations: scenario-driven exercises where teams interpret real-life product P&Ls and cash-flow impacts
• Worked models: participants use tailored Excel tools (gross-to-net waterfall, rebate accrual engine, NPV calculator) to quantify and visualise financial outcomes
•  Regulatory crosslinks: each finance topic is tied to live UK and global regulatory sources (KPMG, GOV.UK, EMA, OECD, ABPI)
• Capstone session: a group-based simulation integrating finance, compliance, and strategy to manage a hypothetical product through a complex pricing and supply chain challenge

Delegates will benefit from a toolkit for ongoing reference, including:

• Excel models: gross-to-net waterfall, rebate accrual engine, NPV scenario tool
• Checklists: VPAG forecasting checklist, ABPI/EFPIA disclosure template, BEPS Pillar Two readiness scan, GxP/GVP financial triggers, DSCSA/FMD compliance tracker
• Reference compendium: summaries of key regulatory and financial frameworks, including IFRS, OECD, MHRA, and ABPI updates.

Key references (standardised citations):

• GOV.UK – Voluntary Scheme for Branded Medicines (2024–2028)
• KPMG Pharma Accounting Updates (Revenue Recognition & IFRS Applications)
• EMA – Good Manufacturing Practice and Serialization Guidelines
• OECD – Base Erosion and Profit Shifting (Pillar Two Framework)
• ABPI – Code of Practice (2024)
• MHRA – GxP Data Integrity Guidance

All financial and regulatory frameworks used in this training reflect the latest publicly available
guidance at the time of delivery. (VPAG rates, DSCSA/FMD timelines, OECD BEPS Pillar
Two thresholds, etc., are subject to periodic revision.)

Browse our extensive selection of Life Sciences training courses for industry-leading insights into a range of topics. These include Medical Devices, IVDs, Biotech and Biopharma, Animal Health and Pharmaceutical training courses.

Benefits of attending

By the end of the course, participants will be able to:

• Interpret a pharmaceutical Profit & Loss statement, identifying the impact of rebates, chargebacks, clawbacks, and returns on gross-to-net revenue
• Apply IFRS 15, IAS 38, and IAS 37 standards to real-world pharmaceutical settings, understanding how revenue recognition, development capitalisation, and provisions interact within R&D and market access portfolios
• Navigate the UK VPAG 2024–2028 pricing framework, model revenue implications of NICE and HTA outcomes, and integrate these into business forecasts
• Recognise the financial consequences of GxP, GMP, and MHRA compliance deviations - from yield losses and write-offs to impairments
• Integrate key compliance frameworks (ABPI/EFPIA, UK Bribery Act, US FCPA, Anti-Kickback Statute, Sunshine Act/Open Payments) into SOPs and finance controls
• Understand OECD BEPS Pillar Two and global minimum tax reforms for multinational pharma operations, and model their impact on tax and transfer pricing decisions
• Assess how serialisation and traceability regulations (EU FMD and US DSCSA 2024/2025) influence financial exposure, inventory management, and working capital.

Who should attend?

This programme has been designed specifically for senior and mid-level managers, team leaders and technical specialists from R&D, clinical, regulatory, commercial, sales and marketing, manufacturing, distribution and purchasing in the pharmaceutical industry.

• General managers and team leaders
• Operations directors
• Business unit heads of department
• Technical specialists from R&D and clinical
• Medical affairs professionals
• Commercial and brand managers
• Quality assurance managers
• Regulatory affairs managers
• Procurement and supply chain managers
• Market access and pricing managers
• Legal and compliance officers
• Finance business partners transitioning into strategic finance roles
• Non-financial executives preparing for senior leadership roles

Enrol/reserve